Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
32 participants
OBSERVATIONAL
2022-09-19
2023-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Drift-Reduction for Improved FFR Using Fiberoptic Technology (DRIFT) Study
NCT03848650
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
NCT05491668
PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)
NCT05493904
Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty
NCT02065102
Comparison of Devices Evaluating Fractional Flow Reserve in Coronary Arteries
NCT03052803
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A maximum of 137 subjects will be enrolled in 5 to 10 sites in Spain to obtain the required minimum of 137 lesions (see section 11.2 Sample Size Determination) The main hypothesis is that the specificity to predict ischemic lesions in TAVR candidates based on a pre-TAVR dPR ≤ 0.89 is superior compared to the specificity based on angiography alone (both QCA and visual assessment of the stenosis \>50%), taking the post-TAVR FFR value of ≤ 0.80 as a reference for positive lesions.
The pressure guidewire used to measure dPR and FFR during diagnostic angiography is the commercially available (CE-marketed) OptoWire family of pressure guidewires from OpSens Inc.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dPR and FFR
Subjects with aortic stenosis who are considered for TAVR will undergo a physiological assessment and prediction of ischemic coronary lesions pre- and post-TAVR by using Opsens non-hyperemic dPR and/or Opsens FFR
dPR and FFR
OpSens non-hyperemic dPR and/or OpSens FFR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dPR and FFR
OpSens non-hyperemic dPR and/or OpSens FFR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a degenerative aortic stenosis with mean valvular gradient ≥40 mmHg
* Subject has a formal heart-team indication for TAVR
* Subject has one or more stable coronary stenosis lesions 30-90% by visual estimation, in a vessel over 2 mm in diameter, and which is amenable for pressure-wire analysis
* Subject agrees to participate in the study and is able to sign the informed consent form
Exclusion Criteria
* Subject has asthma or acute bronchospasm
* Subject has unstable angina or myocardial infarction
* Subject meets any contraindication in the applicable OptoWire IFU
* Subject is pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Opsens, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Enrique Gutierrez Ibanes, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Gregoio Maranon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitari Germans Trias i Pujol
Badalona, , Spain
Hospital Gregorio Maranon
Madrid, , Spain
Hospital Virgen de la Victoria
Málaga, , Spain
Hospital Clinico de Santiago
Santiago de Compostela, , Spain
Hospital Clinico Universitario de Valladolid
Valladolid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRIME CLASS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.